Glycoconjugate Vaccine Containing Escherichia coli O157:H7 O-Antigen Linked with Maltose-Binding Protein Elicits Humoral and Cellular Responses

Emerging Principles for the Therapeutic Exploitation of Glycosylation

(2014) Martin Dalziel et al.   SCIENCE

Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis

(2013) J. Cuccui et al.   Open Biology

Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS)

(2012) Paul N Goldwater et al.   BMC Medicine

Glycoconjugate vaccines

(2012) David Pace   EXPERT OPINION ON BIOLOGICAL THERAPY

Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component

(2012) Michael Wetter et al.   GLYCOCONJUGATE JOURNAL

Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis

(2012) Jeremy A Iwashkiw et al.   Microbial Cell Factories

Comparative effects of carrier proteins on vaccine-induced immune response

(2011) Markus Knuf et al.   VACCINE

Production of Secretory and Extracellular N-Linked Glycoproteins inEscherichia coli

(2010) Adam C. Fisher et al.   APPLIED AND ENVIRONMENTAL MICROBIOLOGY

Production of glycoprotein vaccines in Escherichia coli

(2010) Julian Ihssen et al.   Microbial Cell Factories